Form 4: Gilead CEO Sells 10,000 Shares Under 10b5-1 Plan

Gilead Sciences CEO Daniel O'Day sold 10,000 shares of common stock on November 28, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences, Inc. (GILD), reported transactions involving the sale of common stock.
• On November 28, 2025, Mr. O'Day disposed of a total of 10,000 shares of Gilead Sciences common stock.
• The sales were executed in two separate transactions: 3,212 shares at an average price of $125.9116 per share and 6,788 shares at an average price of $126.8438 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on February 28, 2025.
• Following these reported transactions, Mr. O'Day beneficially owns 571,203 shares of Gilead Sciences common stock.

Sentiment

Score: 5

Explanation: The filing is a routine insider transaction report (Form 4) detailing a pre-scheduled sale under a 10b5-1 plan. Such transactions are generally considered neutral as they are often for personal financial planning and not indicative of new company-specific information.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. Insider sales under a 10b5-1 plan are common practice for executives to diversify holdings and manage liquidity in a pre-scheduled, compliant manner.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, is a routine event and typically has minimal direct impact on the company's operational or strategic direction. It represents a diversification of personal assets rather than a statement on company prospects.

Key Dates

Keywords

Gilead Sciences, GILD, Daniel O'Day, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals